Monoclonal antibody · Activator of muscle, skeletal receptor tyrosine-protein kinase (MuSK) (MUSK) · developed by argenx
Adimanebart is a humanized agonistic monoclonal antibody that binds and activates muscle-specific kinase (MuSK), a transmembrane protein on skeletal muscle cells that is central to forming and maintaining the neuromuscular junction. It is being studied in spinal muscular atrophy, congenital myasthenic syndrome, and amyotrophic lateral sclerosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07746089 | Phase 3 | Congenital Myasthenic Syndrome | Not yet recruiting | ARGX |
| NCT07287982 | Phase 2 | Spinal Muscular Atrophy (SMA) | Recruiting | ARGX |
| NCT06441682 | Phase 2 | Amyotrophic Lateral Sclerosis | Terminated | ARGX |
| NCT07673601 | Phase 1 | Healthy Volunteers (HV) | Recruiting | ARGX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CMSCongenital Myasthenic SyndromeHealthy VolunteerHealthy Volunteers (HV)Spinal Muscular Atrophy (SMA)Amyotrophic Lateral Sclerosis
Updated Oct 11, 2026. Something wrong or missing? Report it on the ARGX page.
See ARGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ARGX catalysts and pipeline →